

A Letter to Our Valued Partners

As you know we are facing an unprecedented situation as the COVID-19 pandemic continues to impact the world around us. During this time, we wanted to update you on how L7 is approaching this evolving situation in order to ensure we can continue to support the important work of our valued customers.

The L7 mission to revolutionize the scientific process by streamlining process and data management and thereby accelerate precision health across life sciences, healthcare, and food value-chains is even more important today than ever before in light of current conditions. During this time, we remain fully operational and committed to working with the scientists, physicians, IT professionals, and data managers who are diagnosing rare diseases, profiling tumor genotypes, developing new crops, protecting food supplies, and producing immunotherapies to fight cancer.

As a company, L7 has taken measures to ensure the health and safety of our employees following the guidelines provided by the CDC and local authorities. Additionally we are working closely with each of our clients to mitigate the impact of travel restrictions on ESP implementations through our virtual delivery model. Finally, we have begun establishing partnerships with diagnostics providers to deliver ready-to-go COVID-19 workflows that will be made available for testing labs around the US. As testing reagent shortages are addressed, laboratory capacity will become the limitation in diagnosing COVID-19 so we are investing now to ensure broad access to these critically important tests.

As we go forward, we commit to keeping you updated as the situation evolves. Please do not hesitate to contact us if you have any questions or concerns.

Vasu Rangadass

President & CEO
L7 Informatics Inc